1. Home
  2. EDTK vs SCLX Comparison

EDTK vs SCLX Comparison

Compare EDTK & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillful Craftsman Education Technology Limited

EDTK

Skillful Craftsman Education Technology Limited

SELL

Current Price

$0.90

Market Cap

14.6M

Sector

Real Estate

ML Signal

SELL

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$0.57

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDTK
SCLX
Founded
2013
2011
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6M
12.0M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
EDTK
SCLX
Price
$0.90
$0.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.8K
★ 73.1K
Earning Date
08-12-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $30,253,000.00
Revenue This Year
N/A
$118.16
Revenue Next Year
N/A
$186.31
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.80
$0.54
52 Week High
$1.36
$23.03

Technical Indicators

Market Signals
Indicator
EDTK
SCLX
Relative Strength Index (RSI) 50.83 8.42
Support Level $0.86 N/A
Resistance Level $1.04 $7.77
Average True Range (ATR) 0.07 0.17
MACD 0.01 -0.04
Stochastic Oscillator 44.57 2.80

Price Performance

Historical Comparison
EDTK
SCLX

About EDTK Skillful Craftsman Education Technology Limited

Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: